Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's top 2 picks
Dec 15, 2024
auto_awesome
Jonathan Faison, who leads the ROTY Biotech Community on Seeking Alpha, shares why he believes Tarsus Pharmaceuticals and SpringWorks Therapeutics are his top investment picks. He discusses Tarsus's drug Xdemvi, which targets demodex blepharitis, and SpringWorks’s promising treatment for desmoid tumors, Oxivio. Faison also dives into the inherent risks in biotech investments, particularly the competitive landscape surrounding Mirdametinib versus more established players like AstraZeneca, highlighting the unique challenges faced by smaller firms.
Tarsus Pharmaceuticals is gaining traction with its drug Xdemvi, which has seen significant price increases and promising early launch metrics.
SpringWorks Therapeutics is recognized for its potential with the drug Oxivio, capturing a large market share and expected to grow through upcoming launches.
Deep dives
Tarsus Pharmaceuticals: A Promising Investment
Tarsus Pharmaceuticals has emerged as a notable investment opportunity due to its lead drug, Xdemvi, which targets demodex blepharitis. Initially met with skepticism, Xdemvi has demonstrated strong early launch metrics, leading to a significant price increase from $15 to the mid-forties. The company's current market cap of $1.8 billion reflects a valuation that could still appreciate, with only one to one-and-a-half times projected peak sales factored in. Analysts expect that the positive trajectory of launch metrics will continue into 2025, promising further growth for investors who hold their positions.
Springworks Therapeutics: Positioned for Growth
Springworks Therapeutics stands out as an early-stage investment with significant potential, particularly with its drug Oxivio for treating desmoid tumors. Recent data shows that over 90% of physicians plan to use Oxivio for frontline treatment, which has already captured a 70% market share among new prescriptions. With a conservative enterprise value estimation of $2.3 billion against projected peak sales of $1 billion, the stock is considered undervalued at around $37. The company is gearing up for multiple key launches in the coming year, positioning it well for robust growth as it navigates the competitive landscape against larger pharmaceutical companies.
1.
Exploring Promising Biotech Investments: Tarsus and SpringWorks
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics (0:30). Data risk for Ogsiveo and Mirdametinib (5:50). This is an excerpt from a recent episode.